arrow
D

Dinesh Khanna

university of michigan scleroderma program
H指数:102
被引数:5.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Advances in imaging for systemic sclerosis

系统性硬化症影像学进展

2026-07-310
PRE
Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study

拉利尼帕格治疗肺动脉高压(ADVANCE OUTCOMES):一项随机、双盲、安慰剂对照的3期研究

2026-07-280
OAAI
Autoantibody associations in patients with early diffuse cutaneous systemic sclerosis: the prospective registry of early systemic sclerosis

早期弥漫性皮肤系统性硬化症患者中的自身抗体关联:早期系统性硬化症前瞻性登记研究

2026-07-010
PRE
Multi-cytokine based TWAS for seven inflammatory skin disorders identify candidate causal genes in keratinocytes

基于多细胞因子法的转录组加权关联分析在七种炎症性皮肤疾病中识别角蛋白细胞中的候选因果基因

2026-05-260
OAAI
Multimodal analyses of early, untreated systemic sclerosis skin identify a proinflammatory vascular niche of macrophage-fibroblast signaling

早期未经治疗的系统性硬化症皮肤的多模态分析识别出巨噬细胞-成纤维细胞信号传导的促炎血管微环境

2026-02-090
PRE
Prospective SARS-CoV-2 additional vaccination in immunosuppressanttreated individuals with autoimmune diseases in a randomized controlled trial

在随机对照试验中,免疫抑制治疗的自身免疫性疾病患者中SARS-CoV-2加强疫苗接种的前瞻性研究

2026-01-090
OA
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

联合使用吡非尼酮与霉酚酸酯治疗系统性硬化症相关性间质性肺疾病(硬皮病肺研究III):一项研究者发起的、多中心、随机、双盲、安慰剂对照的2期临床试验

2025-11-260
OAAI
Risk factors for interstitial lung disease in early rheumatoid arthritis and external validation of screening strategies: a cross-sectional analysis of the prospective SAIL-RA cohort in the USA

早期类风湿关节炎间质性肺病的危险因素及筛查策略的外部验证:美国前瞻性SAIL-RA队列的横断面分析

2025-10-140
PRE
Morphological reprogramming of primary cilia length mitigates the fibrotic phenotype in fibroblasts across diverse fibrotic conditions

原代纤毛长度形态的重编程可减轻多种纤维化条件下的成纤维细胞纤维化表型

2025-10-010
PRE
'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosis

“我这样做对吗?”——医师对系统性硬化症临床试验中全球评估的看法

2025-09-010
OAAI
Hand swelling and other non-Raynaud's symptoms as the initial presentation of systemic sclerosis: prevalence and clinical associations in two U.S. cohorts

手部肿胀和其他非雷诺现象症状作为系统性硬化症的初始表现:在美国两个队列中的患病率及临床关联

2025-05-190
PREAI
Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based study

系统性硬化症自体造血干细胞移植后疾病进展的管理:一项基于国际问卷调查的结果

2025-04-010
OAAI
Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study

血清I型干扰素评分作为弥漫性皮肤系统性硬化症患者疾病活动性生物标志物:一项回顾性队列研究

2025-03-310
PRE
Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics

细胞外基质相关诊断和治疗的研究进展

2025-03-100
OAAI
Impact of Scleroderma-Associated Autoantibodies on Clinical Outcome Assessments: Post Hoc Analysis From a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial of Tocilizumab in Scleroderma

系统性硬化症相关自身抗体对临床结局评估的影响:来自一项随机、双盲、安慰剂对照的系统性硬化症III期试验的后期分析(托珠单抗治疗系统性硬化症)

2025-01-231
OAAI